RxDoctor Payments Data

Andrew Peters, MD

Cardiovascular Disease · Chicago, ILNPI 1154664944

Payments from drug & device makers

$6,279in general payments, 2019–2025

Across 67 payments — averaging $93.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Heartflow, Inc.$2K
  • Edwards Lifesciences$1K
  • Impulse Dynamics (USA) Inc.$95
  • Ironshore Pharmaceuticals Inc.$92
  • Novartis$92
  • plus $341 from 11 others

What the payments were for

  • Consulting fees$1,29021%
  • Travel & lodging$3,02548%
  • Food & beverage$1,96431%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,279 in reported general payments places this provider in the 70th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$96,948
Medicare patients
649
Services billed
1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$90,940
FarxigaDapagliflozin Propanediol90$75,357
EntrestoSacubitril/Valsartan49$45,629
Repatha SureclickEvolocumab55$36,703
XareltoRivaroxaban26$30,533
JardianceEmpagliflozin13$11,137
Praluent PenAlirocumab18$9,068
Atorvastatin Calcium245$4,088
Rosuvastatin Calcium208$3,879
Ezetimibe88$2,465
Metoprolol Succinate192$2,222
Carvedilol105$1,319
Valsartan28$902
Losartan Potassium92$886
Nitroglycerin37$765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$90,94087 claims
NovartisEntresto$92$45,62949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →